# Navient LLC: financial statements, quarterly

NAVI · Nasdaq · CIK 1593538 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/navi.md) · [Financials](/companies/navi/financials.md) · [Filings](/companies/navi/filings.md) · [Insiders](/companies/navi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/navi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [85.0](/filings/0000950170-24-119084.md) | [81.0 d](/filings/0000950170-25-032042.md) | [77.0](/filings/0000950170-24-047619.md) | [81.0](/filings/0000950170-24-086072.md) | [70.0](/filings/0000950170-24-119084.md) | [43.0 d](/filings/0000950170-25-032042.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | [879](/filings/0000950170-23-055266.md) | [921 d](/filings/0000950170-24-020149.md) | [875](/filings/0000950170-24-047619.md) | [843](/filings/0000950170-24-086072.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [31.0](/filings/0000950170-24-119084.md) | [(8.0) d](/filings/0001193125-26-076753.md) | [15.0](/filings/0000950170-25-061089.md) | [12.0](/filings/0000950170-25-100241.md) | [14.0](/filings/0001193125-25-256361.md) | [2.0 d](/filings/0001193125-26-076753.md) | [(3.0)](/filings/0001193125-26-191605.md) | [4.0](/filings/0001193125-26-340245.md) | [(31.0)](/filings/0001193125-25-256361.md) | [(2.0) d](/filings/0001193125-26-076753.md) | [15.0](/filings/0001193125-26-191605.md) | [14.0](/filings/0001193125-26-340245.md) |
| Net income | $m | [79.0](/filings/0000950170-24-119084.md) | [(28.0) d](/filings/0001193125-26-076753.md) | [73.0](/filings/0000950170-25-061089.md) | [36.0](/filings/0000950170-25-100241.md) | [(2.0)](/filings/0001193125-25-256361.md) | [24.0 d](/filings/0001193125-26-076753.md) | [(2.0)](/filings/0001193125-26-191605.md) | [14.0](/filings/0001193125-26-340245.md) | [(86.0)](/filings/0001193125-25-256361.md) | [(5.0) d](/filings/0001193125-26-076753.md) | [17.0](/filings/0001193125-26-191605.md) | [25.0](/filings/0001193125-26-340245.md) |
| Diluted EPS | $ per share | [0.65](/filings/0000950170-24-119084.md) | not reported | [0.64](/filings/0000950170-25-061089.md) | [0.32](/filings/0000950170-25-100241.md) | [(0.02)](/filings/0001193125-25-256361.md) | not reported | [(0.02)](/filings/0001193125-26-191605.md) | [0.13](/filings/0001193125-26-340245.md) | [(0.87)](/filings/0001193125-25-256361.md) | not reported | [0.17](/filings/0001193125-26-191605.md) | [0.26](/filings/0001193125-26-340245.md) |
| Basic EPS | $ per share | [0.66](/filings/0000950170-24-119084.md) | not reported | [0.65](/filings/0000950170-25-061089.md) | [0.32](/filings/0000950170-25-100241.md) | [(0.02)](/filings/0001193125-25-256361.md) | not reported | [(0.02)](/filings/0001193125-26-191605.md) | [0.14](/filings/0001193125-26-340245.md) | [(0.87)](/filings/0001193125-25-256361.md) | not reported | [0.18](/filings/0001193125-26-191605.md) | [0.27](/filings/0001193125-26-340245.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [1.0](/filings/0000950170-24-119084.md) | [0.8](/filings/0001193125-26-076753.md) | [0.8](/filings/0000950170-25-061089.md) | [1.1](/filings/0000950170-25-100241.md) | [1.1](/filings/0001193125-25-256361.md) | [0.7](/filings/0001193125-26-076753.md) | [0.6](/filings/0001193125-26-191605.md) | [0.7](/filings/0001193125-26-340245.md) | [0.6](/filings/0001193125-25-256361.md) | [0.6](/filings/0001193125-26-340245.md) | [0.6](/filings/0001193125-26-191605.md) | [0.8](/filings/0001193125-26-340245.md) |
| Total assets | $bn | [63.4](/filings/0000950170-23-055266.md) | [61.4](/filings/0000950170-25-032042.md) | [59.0](/filings/0000950170-24-047619.md) | [56.6](/filings/0000950170-24-086072.md) | [53.4](/filings/0000950170-24-119084.md) | [51.8](/filings/0001193125-26-076753.md) | [51.0](/filings/0000950170-25-061089.md) | [50.2](/filings/0000950170-25-100241.md) | [49.3](/filings/0001193125-25-256361.md) | [48.7](/filings/0001193125-26-340245.md) | [48.0](/filings/0001193125-26-191605.md) | [47.3](/filings/0001193125-26-340245.md) |
| Total liabilities | $bn | [60.5](/filings/0000950170-23-055266.md) | [58.6](/filings/0000950170-25-032042.md) | [56.3](/filings/0000950170-24-047619.md) | [53.9](/filings/0000950170-24-086072.md) | [50.7](/filings/0000950170-24-119084.md) | [49.1](/filings/0001193125-26-076753.md) | [48.4](/filings/0000950170-25-061089.md) | [47.7](/filings/0000950170-25-100241.md) | [46.9](/filings/0001193125-25-256361.md) | [46.3](/filings/0001193125-26-340245.md) | [45.6](/filings/0001193125-26-191605.md) | [44.9](/filings/0001193125-26-340245.md) |
| Long-term debt | $bn | [54.9](/filings/0000950170-23-055266.md) | [53.4](/filings/0000950170-25-032042.md) | [50.8](/filings/0000950170-24-047619.md) | [47.5](/filings/0000950170-24-086072.md) | [44.7](/filings/0000950170-24-119084.md) | [43.2](/filings/0001193125-26-076753.md) | [42.9](/filings/0000950170-25-061089.md) | [42.3](/filings/0000950170-25-100241.md) | [41.4](/filings/0001193125-25-256361.md) | [40.6](/filings/0001193125-26-340245.md) | [39.2](/filings/0001193125-26-191605.md) | [40.1](/filings/0001193125-26-340245.md) |
| Short-term borrowings | $bn | [4.7](/filings/0000950170-23-055266.md) | [4.2](/filings/0000950170-25-032042.md) | [4.4](/filings/0000950170-24-047619.md) | [5.3](/filings/0000950170-24-086072.md) | [5.3](/filings/0000950170-24-119084.md) | [5.1](/filings/0001193125-26-076753.md) | [4.9](/filings/0000950170-25-061089.md) | [4.8](/filings/0000950170-25-100241.md) | [4.9](/filings/0001193125-25-256361.md) | [5.1](/filings/0001193125-26-340245.md) | [5.9](/filings/0001193125-26-191605.md) | [4.2](/filings/0001193125-26-340245.md) |
| Shareholders' equity | $bn | [2.9](/filings/0000950170-24-119084.md) | [2.8](/filings/0001193125-26-076753.md) | [2.8](/filings/0000950170-25-100241.md) | [2.7](/filings/0001193125-25-256361.md) | [2.7](/filings/0001193125-25-256361.md) | [2.6](/filings/0001193125-26-340245.md) | [2.6](/filings/0001193125-26-340245.md) | [2.6](/filings/0001193125-26-340245.md) | [2.4](/filings/0001193125-25-256361.md) | [2.4](/filings/0001193125-26-340245.md) | [2.4](/filings/0001193125-26-340245.md) | [2.4](/filings/0001193125-26-340245.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [122 d](/filings/0000950170-24-119084.md) | [310 d](/filings/0001193125-26-076753.md) | [182](/filings/0000950170-25-061089.md) | [279 d](/filings/0000950170-25-100241.md) | [(10.0) d](/filings/0001193125-25-256361.md) | [8.0 d](/filings/0001193125-26-076753.md) | [71.0](/filings/0001193125-26-191605.md) | [126 d](/filings/0001193125-26-340245.md) | [70.0 d](/filings/0001193125-25-256361.md) | [174 d](/filings/0001193125-26-076753.md) | [(47.0)](/filings/0001193125-26-191605.md) | [143 d](/filings/0001193125-26-340245.md) |
| Dividends paid | $m | [19.0 d](/filings/0000950170-24-119084.md) | [19.0 d](/filings/0001193125-26-076753.md) | [18.0](/filings/0000950170-25-061089.md) | [17.0 d](/filings/0000950170-25-100241.md) | [18.0 d](/filings/0001193125-25-256361.md) | [17.0 d](/filings/0001193125-26-076753.md) | [16.0](/filings/0001193125-26-191605.md) | [16.0 d](/filings/0001193125-26-340245.md) | [16.0 d](/filings/0001193125-25-256361.md) | [15.0 d](/filings/0001193125-26-076753.md) | [15.0](/filings/0001193125-26-191605.md) | [15.0 d](/filings/0001193125-26-340245.md) |
| Share repurchases | $m | [75.0 d](/filings/0000950170-24-119084.md) | [70.0 d](/filings/0001193125-26-076753.md) | [43.0](/filings/0000950170-25-061089.md) | [38.0 d](/filings/0000950170-25-100241.md) | [33.0 d](/filings/0001193125-25-256361.md) | [65.0 d](/filings/0001193125-26-076753.md) | [35.0](/filings/0001193125-26-191605.md) | [24.0 d](/filings/0001193125-26-340245.md) | [26.0 d](/filings/0001193125-25-256361.md) | [26.0 d](/filings/0001193125-26-076753.md) | [23.0](/filings/0001193125-26-191605.md) | [3.0 d](/filings/0001193125-26-340245.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [141](/filings/0000950170-23-055266.md) | [130](/filings/0000950170-24-047619.md) | [125](/filings/0000950170-24-086072.md) | [121](/filings/0000950170-24-119084.md) | [114](/filings/0000950170-25-061089.md) | [112](/filings/0000950170-25-100241.md) | [108](/filings/0001193125-25-256361.md) | [102](/filings/0001193125-26-191605.md) | [101](/filings/0001193125-26-340245.md) | [98.0](/filings/0001193125-25-256361.md) | [96.0](/filings/0001193125-26-191605.md) | [95.0](/filings/0001193125-26-340245.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 93,783,828 at 2026-06-30, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-340245.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.